Search:
   

Tuesday, February 10, 2026

Equity Corporate Actions Alert #2026 - 89
(UPDATED: Merger Closed) Spin-Off/Distribution and Merger Information for Avidity Biosciences, Inc. (RNAM)

Category:

  • Industry Announcement

Markets Impacted:

Contact Information:

Resources:

On February 2, 2026, Avidity Biosciences, Inc. (RNAM) announced a record date of February 12, 2026, for the spin-off of Atrium Therapeutics, Inc. in connection with the previously announced acquisition of Avidity Biosciences, Inc. by Novartis AG (NYSE: NVS). Shareholders approved the transaction on February 26, 2026. The details for the spin-off are as follows:

Parent Company/Issue: Avidity Biosciences, Inc. Common Stock
CUSIP: 05370A108
Symbol: RNAM
Record Date: February 12, 2026
Payment Date: February 26, 2026
EX Date: February 27, 2026
Due Bill Redeemable Date: February 27, 2026
Ratio of Spin-Off/ Distribution:
 One (1) share of Atrium Therapeutics, Inc. Common Stock for every ten (10) shares of Avidity Biosciences, Inc. (RNAM) held.

Atrium Therapeutics, Inc. is expected to list on the Nasdaq Global Select Market on February 27, 2026. There will not be a when issued market for Atrium Therapeutics Inc. or an ex distribution when issued market for Avidity Biosciences, Inc. listed on Nasdaq. Upon effectiveness of the merger of Avidity Biosciences, Inc. (RNAM) with Novartis AG, Atrium Therapeutics, Inc. will be assigned the symbol RNA upon the suspension of Avidity Biosciences Inc. from Nasdaq. The details are as follows:

Company Name: Atrium Therapeutics, Inc.
CUSIP#: 04965N104
Symbol: RNA
Expected First Trade Date: February 27, 2026

At a special meeting held on February 26, 2026, the shareholders of Avidity Biosciences, Inc. (RNAM) approved the proposed merger with Novartis AG (NVS). The merger closed prior to the market open on February 27, 2026. In anticipation of the closing, the stock was halted immediately following the after-hours session at or around 7:50 p.m. on February 26, 2026. The stock will remain halted on the day of closing (February 27th) and will be suspended effective March 2, 2026. The details are as follows:

Company Name/Issue: Avidity Biosciences, Inc. Common Stock
CUSIP#: 05370A108
Symbol: RNAM
Last Trading Date: February 26, 2026
Marketplace Effective Date for Suspension: March 2, 2026
Merger Consideration: $72.00 for each share held.

Additionally, prior to the completion of the merger, Avidity Biosciences, Inc. underwent a symbol change from RNA to RNAM effective February 26, 2026. The details for the symbol change are as follows:

Company Name: Avidity Biosciences, Inc.
CUSIP#: 05370A108
Symbol: RNA
New Symbol: RNAM
Effective Date: February 26, 2026

For information regarding this announcement, contact Nasdaq Corporate Data Operations at +1 877 308 0523.

If you would like to register as a market maker in RNA contact Nasdaq Trading Services at +1 212 231 5100.

Email Alert Subscriptions:
Nasdaq offers customers the ability to self select news delivery across various Nasdaq markets. Create and maintain a profile for updating alert preferences and contact information. Visit the enrollment form on the Nasdaq Trader website and sign up today! Please note that if you choose to unsubscribe from an email list, you may no longer receive potentially critical emails from the NASDAQ Stock Market regarding Nasdaq's trading and data products, regulatory issues or marketplace initiatives. To unsubscribe, also click on the enrollment form

Please follow Nasdaq on Facebook RSS and Twitter.

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: business.nasdaq.com.

View NASDAQTrader.com Mobile